Cellectar Biosciences (CLRB) Says Preclinical Data Highlighting Uptake and Enhanced Anti-Tumor Effects of its CLR 131 in Head and Neck Cancer Presented at AACR
Tweet Send to a Friend
Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
